These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 27405908)

  • 1. Promising Psychotherapeutic Effects of the Natural Sugar: Myo-Inositol.
    Vadnal R; Parthasarathy L; Parthasarathy R
    Nutr Neurosci; 1998; 1(1):21-33. PubMed ID: 27405908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential role and therapeutic interests of myo-inositol in metabolic diseases.
    Croze ML; Soulage CO
    Biochimie; 2013 Oct; 95(10):1811-27. PubMed ID: 23764390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders--focus on magnetic resonance spectroscopy (MRS) studies.
    Kim H; McGrath BM; Silverstone PH
    Hum Psychopharmacol; 2005 Jul; 20(5):309-26. PubMed ID: 15880397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining the neuromolecular action of myo-inositol: application to obsessive-compulsive disorder.
    Harvey BH; Brink CB; Seedat S; Stein DJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Jan; 26(1):21-32. PubMed ID: 11853115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of inositol phospholipid and inositol phosphate metabolism in chemoattractant-activated human polymorphonuclear leukocytes.
    Dillon SB; Murray JJ; Uhing RJ; Snyderman R
    J Cell Biochem; 1987 Dec; 35(4):345-59. PubMed ID: 3126197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteration of myo-inositol monophosphatase in Alzheimer's disease brains.
    Shimohama S; Tanino H; Sumida Y; Tsuda J; Fujimoto S
    Neurosci Lett; 1998 Apr; 245(3):159-62. PubMed ID: 9605480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enantiomers of myo-inositol-1,3,4-trisphosphate and myo-inositol-1,4,6 -trisphosphate: stereospecific recognition by cerebellar and platelet myo-inositol-1,4,5-trisphosphate receptors.
    Murphy CT; Bullock AJ; Lindley CJ; Mills SJ; Riley AM; Potter BV; Westwick J
    Mol Pharmacol; 1996 Nov; 50(5):1223-30. PubMed ID: 8913354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic myo-inositol increases rat brain phosphatidylethanolamine plasmalogen.
    Pettegrew JW; Panchalingam K; Levine J; McClure RJ; Gershon S; Yao JK
    Biol Psychiatry; 2001 Mar; 49(5):444-53. PubMed ID: 11274656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlative studies on the effect of carbachol on myo-inositol trisphosphate accumulation, myosin light chain phosphorylation and contraction in sphincter smooth muscle of rabbit iris.
    Howe PH; Akhtar RA; Naderi S; Abdel-Latif AA
    J Pharmacol Exp Ther; 1986 Nov; 239(2):574-83. PubMed ID: 3021957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Muscarinic release of inositol trisphosphate without mobilization of calcium in bovine adrenal chromaffin cells.
    Swilem AM; Yagisawa H; Hawthorne JN
    J Physiol (Paris); 1986; 81(4):246-51. PubMed ID: 3033224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effects of substance P and carbachol on the saturable sodium-dependent uptake process of myo-inositol in rat parotid gland.
    Torrens Y; Dietl M; Beaujouan JC; Glowinski J
    J Pharmacol Exp Ther; 1991 Aug; 258(2):639-46. PubMed ID: 1713964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment with D-myo-inositol trisphosphate reduces infarct size in rabbit hearts: role of inositol trisphosphate receptors and gap junctions in triggering protection.
    Przyklenk K; Maynard M; Darling CE; Whittaker P
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1386-92. PubMed ID: 15919762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor-mediated signalling pathways acting through hydrolysis of membrane phospholipids in cardiomyocytes.
    Lamers JM; De Jonge HW; Panagia V; Van Heugten HA
    Cardioscience; 1993 Sep; 4(3):121-31. PubMed ID: 8400019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationships between receptor binding capacity for norepinephrine, angiotensin II, and vasopressin and release of inositol trisphosphate, Ca2+ mobilization, and phosphorylase activation in rat liver.
    Lynch CJ; Blackmore PF; Charest R; Exton JH
    Mol Pharmacol; 1985 Aug; 28(2):93-9. PubMed ID: 2991741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms involved in receptor-mediated changes of intracellular Ca2+ in liver.
    Williamson JR; Hansen CA; Verhoeven A; Coll KE; Johanson R; Williamson MT; Filburn C
    Soc Gen Physiol Ser; 1987; 42():93-116. PubMed ID: 2850613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epi-inositol and inositol depletion: two new treatment approaches in affective disorder.
    Bersudsky Y; Einat H; Stahl Z; Belmaker RH
    Curr Psychiatry Rep; 1999 Dec; 1(2):141-7. PubMed ID: 11122916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of agonist-induced inositol phosphate metabolism by cyclic adenosine 3',5'-monophosphate in adrenal glomerulosa cells.
    Baukal AJ; Hunyady L; Balla T; Ely JA; Catt KJ
    Mol Endocrinol; 1990 Nov; 4(11):1712-9. PubMed ID: 2280773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cellular language of myo-inositol signaling.
    Gillaspy GE
    New Phytol; 2011 Dec; 192(4):823-839. PubMed ID: 22050576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substrate properties of analogs of myo-inositol.
    Moyer JD; Reizes O; Ahir S; Jiang C; Malinowski N; Baker DC
    Mol Pharmacol; 1988 Jun; 33(6):683-9. PubMed ID: 2837638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmodium falciparum is dependent on de novo myo-inositol biosynthesis for assembly of GPI glycolipids and infectivity.
    Macrae JI; Lopaticki S; Maier AG; Rupasinghe T; Nahid A; Cowman AF; McConville MJ
    Mol Microbiol; 2014 Feb; 91(4):762-76. PubMed ID: 24350823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.